Moreover, the company is also working to improve access ... lowered from a range of $22.50-$24.00 to $4.00-$5.60per share. AZN’s Breztri Meets Goal in Phase III Asthma Studies AstraZeneca ...

AstraZeneca’s AZN late-stage asthma study on inhaled triple ... which can help Wegovy sales to rebound in the second half. Moreover, the company is also working to improve access for Wegovy ...

AstraZeneca PLC closed 19.93% short of its 52-week high of £133.88, which the company achieved on September 3rd.

For what brand would not want its logo to be emphasized? And if a company’s goal is to use its logo to communicate boldness as a brand attribute, the single most obvious, literal, no-brainer way ...

On Friday, AstraZeneca Plc (NASDAQ:AZN) reported topline data from Phase 3 KALOS and LOGOS trials in patients with uncontrolled asthma. KALOS and LOGOS trials assessed the efficacy and safety of ...

The AstraZeneca PLC ADR AZN slipped 1.78% to $67.72 Tuesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.61% to ...

This announcement comes amidst the company's robust Q1 2025 financial performance, which showed significant gains in sales, revenue, and net income. Meanwhile, the broader market rose by 1.8% last ...

London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...

AstraZeneca PLC (NASDAQ:AZN) is a biopharmaceutical company that explores, develops, manufactures, and commercializes prescription medicines. It supplies its products and services to specialty and ...